Congress trades and big insider sales, sent the day they're filed. Free.
Open in Telegram
CLO, CSO and Corp Secretary · AEON Biopharma, Inc. · Class A Common Stock
Open-market purchase
$17K reported value · 6.2% of prior position
Disclosed 0 business days after execution (deadline: 2)
First recorded trade by this actor in this security
2 other actors traded the same direction within 14 days
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 39 | Bancroft Robert E.Director, President and CEO | Open-market purchase | BUY | $20K 152.3K sh | Nov 20, 2026 traded Nov 19, 2026 | |
| 43 | Sy JenniferChief Accounting Officer | Open-market purchase | BUY | $20K 153.8K sh | Nov 20, 2026 traded Nov 19, 2026 | |
| 22 | Daewoong Co., Ltd10% Owner | Other acquisition or disposition | J | $1,124 3,822 sh | Nov 10, 2026 traded Oct 30, 2026 | |
| 31 | Daewoong Co., Ltd10% Owner | In-the-money exercise | X | $1,124 11.24M sh | Nov 10, 2026 traded Oct 30, 2026 | |
| 19 | Daewoong Co., Ltd10% Owner | In-the-money exercise | X | — 11.24M sh | Nov 10, 2026 traded Oct 30, 2026 |
Read directly from the primary public document; every field below is as reported by the filer.
Value = shares × reported price per share
= $17,479
Wilson Alexander Blair filed this Form 4 reporting a open-market purchase of AEON on Nov 20, 2026. It became public on Nov 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
No field has changed since this record was first ingested.
No material filings recorded for this issuer.